Latest Conference Articles

Long-term moderate thyroid hormone suppression therapy is associated with improved outcomes in patients with differentiated thyroid cancer.

Carmelo Nucera, MD, PhD, endocrinologist, assistant professor, Harvard Medical School, Division of Experimental Pathology, Beth Israel Deaconesss Medical Center, Boston, discusses the role of RNA in thyroid cancer

Numerous disease-related variables could serve as prognostic and predictive factors for treatment outcomes with sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer.

First-line afatinib (Gilotrif) improved overall survival (OS) by about 1 year in patients with advanced non–small cell lung cancer (NSCLC) whose tumors harbor EGFR exon 19 deletions according to results from the LUX-Lung 3 and the LUX-Lung 6 phase III randomized trials.

Ramona Dadu, MD, from the MD Anderson Cancer Center, discusses the results of a pilot study that examined the efficacy of CASAD, a natural clay, to reduce medullary thyroid cancer-related diarrhea.

Ramaswamy Govindan, MD, Director, Thoracic Oncology, Co-Director, Section of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the potential for the ALK inhibitor alectinib.

Treatment with PD-1 immunotherapy across various oncology clinical trials has been associated with the induction of painless thyroiditis, characterized by transient thyrotoxicosis and hypothyroidism, in patients with metastatic malignancies

Patients with NSCLC who received postoperative radiation therapy lived 4 months longer on average than patients who did not receive radiation but who had the same disease site, tumor histology, and treatment criteria, according to a large retrospective study.

D. Ross Camidge, MD, PhD, discusses CO-1686 (rociletinib) and AZD9291, two agents that inhibit initial activating EGFR mutations and the T790M resistance mutation.

Ezra Cohen, MD, professor of medicine, UC San Diego Moores Cancer Center, discusses the challenges of treating Medullary Thyroid Cancer (MTC).

Molecular profiling has revealed several tumor markers that could be utilized as therapeutic targets for patients with small cell lung cancer (SCLC) or lung neuroendocrine tumors (NETs).

A new study suggests a knowledge gap in Primary Care Providers' familiarity with screening guidelines could also be a barrier to successful implementation.

Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses the overall survival analysis of the LUX-Lung 3 and LUX-Lung 6 trials.

Biopsies were found to be the most costly tool used in lung cancer diagnosis, and may be performed too frequently based on negative test results and adverse events.

David R. Gandara, MD, from UC Davis Comprehensive Cancer Center, discusses the future of clinical trial designs.

New data being presented at the 84th Annual Meeting of the American Thyroid Association show promise for two molecular tests that help identify indeterminate thyroid nodules as either benign or malignant.

David C. Metz, MBBCh, professor of medicine, co-director, GI Physiology laboratory, Hospital of the University of Pennsylvania, discusses using a multidisciplinary approach to treating neuroendocrine tumors (NETs).

Somatic mutations in the ATRX gene are observed in about 13% of pheochromocytomas/paragangliomas, the first such report of somatic ATRX mutations in these tumors.

Matthew Kulke, MD, comments on some unanswered questions surrounding the treatment of neuroendocrine tumors (NETs).

Low nuclear expression of CDKN1B, a cyclin-dependent kinase inhibitor gene that encodes p27, in gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) appears to be associated with a worse prognosis.

Somatostatin analogs remain the mainstay of medical therapy for symptom control in patients with carcinoid syndrome.

A subcutaneous depot formulation of octreotide has a rapid onset, greater bioavailability, and a similar duration of effect compared with intramuscular octreotide long-acting repeatable.

The rate of PFS with axitinib in patients with advanced carcinoid tumors is promising.

Treatment with the mTOR inhibitor everolimus improved overall survival by 6.34 months over placebo for patients with pancreatic neuroendocrine tumors.

Diane Reidy-Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses an analysis looking at a practical method of determining the site of unknown primary in metastatic neuroendocrine tumors (NETs).

Rodney F. Pommier, MD, professor of surgery, director, Neuroendocrine Tumor Program, Oregon Health & Science University, discusses challenges associated with the treatment of carcinoid syndrome.

Selection of first-line treatments and the rational sequencing of therapies are among the unresolved questions in the treatment of pancreatic neuroendocrine tumors.

James C. Yao, MD, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses key takeaways from the RADIANT-3 trial for a community oncologist.

Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses sequencing agents for the treatment of pancreatic NETs.

Adding saracatinib to vascular endothelial growth factor (VEGF)-targeted therapy did not improve response rates or overall survival while adding to toxicity in VEGF-resistant metastatic renal cell carcinoma